Oncology

• 1. Introduction

  ›

  Oncology begins with a papyrus. Around 3000 BCE, Egyptian physicians encountered something they could not ignore: a bulging tumor of the breast. They wrote it down in what we now call the Edwin Smith papyrus, making that clinical note one of the earliest recorded descriptions of cancer in human history. The field that would eventually rise to confront that ancient terror has a name rooted in a single Greek word. Galen, a physician who lived from 130 to 200 CE, used the term onkos to describe tumors. From that word we get both "oncology" and "oncologist." Two words that today represent an entire world of diagnosis, treatment, research, and care. How does a physician decide whether to cut, to irradiate, or to use chemistry against cancer? What happens when a tumor cannot be fully removed? And what does it mean to treat not just a disease but the full person living with it? Those are the questions oncology has spent centuries learning to ask.

• 2. Reading the Body

  ›

  A patient arrives feeling tired, losing weight without explanation, running fevers that no obvious infection can account for. These are the kinds of nonspecific signals that prompt an oncologist to look further. Medical histories serve as a first screening layer, catching concerns that point toward the possibility of malignancy before more invasive tests begin. From there, the diagnostic toolkit branches in many directions. A biopsy or resection can remove suspicious cells, in part or in whole, so that a pathologist can examine them directly. That tissue examination is considered essential for properly classifying a cancer and charting the course of treatment. When even a tissue diagnosis is not possible, a rare situation oncologists call empirical therapy may be considered, guided by history, X-rays, and scans rather than a confirmed label. Imaging technologies extend the oncologist's reach deep inside the body: CT scanning, MRI, ultrasound, mammography, and X-rays can locate suspicious areas and guide where biopsies are aimed. Nuclear medicine adds further layers, with scintigraphy, positron emission tomography, and single photon emission computed tomography identifying regions of concern that other methods might miss. CT scanning, in particular, carries a dual role: it guides the search for cancer, and it helps determine operability, meaning whether a tumor can realistically be removed in full. Blood tests, including tumor markers, can support a diagnosis for certain cancer types. Immunohistochemical markers can point strongly toward where a primary malignancy originated, even when the original site remains unknown, a situation referred to as malignancy of unknown primary.

• 3. The Question of Treatment

  ›

  Surgery is attempted, when feasible, to remove a tumor entirely. That word entirely carries significant weight. When parts of a tumor will inevitably remain, whether because metastases have spread or because the tumor has grown into a structure too risky to operate on, curative surgery becomes impossible. Oncologists have developed a middle path for some of these cases: debulking, a procedure that reduces the overall volume of tumor tissue even without achieving a full removal. Surgery also appears in palliative roles, such as relieving biliary obstruction or addressing complications from certain brain tumors. Chemotherapy and radiotherapy are used as first-line radical therapies in several malignancies. They also serve an adjuvant purpose: deployed after surgery has removed a visible tumor, to address the statistical risk that cancer will return even when no disease is macroscopically detectable. Both modalities are used in palliative settings too, aiming to improve quality of life and extend it when a disease is clearly incurable. Hormone manipulation has become well established in the treatment of breast and prostate cancer specifically. Monoclonal antibody treatments have grown into a broad category, with examples including Rituximab for lymphoma and Trastuzumab for HER2-positive breast cancer. Checkpoint inhibitors, CAR-T cell therapy, cytokine therapies, and cancer vaccines represent active research and clinical application in the immunotherapy space. For some disorders, such as ALL and AML, the urgency is immediate: these require hospital admission and chemotherapy without delay. Others can be monitored through physical examination, imaging, and blood tests over time.

• 4. When Cure Is Not the Goal

  ›

  Palliative care in oncology addresses something surgery and chemotherapy cannot always reach. Pain, nausea, anorexia, fatigue, immobility, depression: these are the lived realities for many patients with advanced cancer. Personal dignity is named explicitly as something that may be affected. Moral and spiritual concerns are acknowledged as part of the picture. For pediatric patients, the source notes that the number who reach remission is much higher than the general cancer population, though ongoing issues with symptom control remain present even there. Palliative care has matured into a specialty in its own right, closely allied with oncology but distinct from it. It now functions as an essential part of the multidisciplinary team that surrounds a cancer patient. The collaboration between an oncologist managing the disease and a palliative care team managing suffering is not a concession of defeat; it is recognized as good medicine.

• 5. Specialties Within Specialties

  ›

  Oncology divides into four main branches. Clinical oncology combines systemic therapies with radiation. Medical oncology covers chemotherapy, targeted therapy, immunotherapy, and hormonal therapy. Radiation oncology focuses exclusively on treatment by radiation. Surgical oncology treats cancer through surgery. Beneath those four branches, sub-specialties proliferate. Pediatric oncology concentrates on cancer in children. Geriatric oncology attends to cancers in elderly patients. Gynecologic oncology focuses on the female reproductive system. Neuro-oncology targets brain cancers. Hemato-oncology covers blood cancers and stem cell transplantation. There are specialties organized around anatomy, including thoracic oncology for lung, mediastinum, esophagus, and pleura; gastrointestinal oncology for stomach, colon, rectum, liver, gallbladder, and pancreas; and ocular oncology for cancers of the eye. Cardiooncology is listed as an emerging specialty, a branch of cardiology that addresses the cardiovascular effects of cancer and its treatments. Even veterinary oncology appears on the list, treating cancer in animals. Psycho-oncology addresses the psychosocial dimensions of a cancer diagnosis and its treatment. Mathematical oncology and molecular oncology, focused on diagnostic methods at the molecular level, represent the field's reach into quantitative and genetic science.

• 6. Research and the Road Forward

  ›

  Next-generation sequencing and whole-genome sequencing have fundamentally changed how cancers are understood. The identification of novel genetic and molecular markers is reshaping both diagnosis and treatment, pointing the field toward personalized medicine rather than one-size approaches. Therapeutic trials in oncology often involve patients drawn from many hospitals across a region. In the United Kingdom, large studies are coordinated by bodies including Cancer Research UK, the Medical Research Council, the European Organisation for Research and Treatment of Cancer, and the National Cancer Research Network. Among the most valued companies whose leading products fall in oncology are Pfizer from the United States, Roche from Switzerland, Merck from the United States, AstraZeneca from the United Kingdom, Novartis from Switzerland, and Bristol-Myers Squibb from the United States. Their work spans kinase inhibitors, antibodies, immuno-oncology, and radiopharmaceuticals. The same papyrus that recorded that bulging tumor of the breast in 3000 BCE also records how long human beings have been trying to understand what cancer is. Whole-genome sequencing, barely conceivable a generation ago, is now among the tools those efforts use.